MetaVia is trading 5.11% higher at $1.44 after the October 15 regular-session close of $1.37, with no verified company-specific catalyst identified. - The latest company-specific news found was an October 13 appointment of a chief medical officer, not a confirmed October 15 catalyst. - Broader market context was mixed and does not establish a clear reason for the move.